The pharmaceutical industry: a further study in corporate power.
This article represents an updated version of previous research conducted on the United States pharmaceutical industry. The unstated purpose of this article is to present new findings which supplement the earlier research. This article describes three aspects of the United States pharmaceutical industry: its strategy and structure within the world market, its global expansion beyond the territorial boundaries of the United States, and its interlocking directorates with banking institutions. The thesis presented here is twofold: first, the United States pharmaceutical industry has become increasingly integrated into larger and more heterogeneous production units operating on the world market; and second, the United States pharmaceutical industry has become increasingly linked to large United States banking firms through interlocking directorates.
D004345:Drug Industry; D004467:Economics; D005252:Fees, Pharmaceutical; D006075:Governing Board; D007449:Investments; D009935:Organizational Affiliation; D010330:Patents as Topic; D012106:Research; D013678:Technology, Pharmaceutical / Q000191:economics*; D014481:United States